Activity of Cannabinoids in Type II-Diabetes

Abstract

The present research is a theoretical study of the medicinal use of Cannabis (cannabinoids) compounds in Type II Diabetes based on literature citing animal models and available clinical evidence from human studies. The study emphasizes the positive physiological actions and benefits of cannabinoid compounds in Type II Diabetes. The pharmacological activities of cannabinoid compounds in Type II Diabetes have been studies only in limited human clinical trials that were often not conducted as evidence-based (i.e., following the established rules of probability and scientific methodology). In the United States, the Federal Drug Enforcement Agency (DEA) continues to classify all natural cannabinoid compounds as “Schedule 1” drugs (i.e., dangerous illegal narcotics on par with heroin or LSD). As a result of this classification as illegal, many human clinical studies of Cannabis compounds in medical therapy have been thwarted and continue to face a dearth of funding for research grants and drug development by the pharmaceutical houses, universities, and industry. The future looks bright, though, for Cannabis as a medication source as many states (including all the U.S. western states) have decriminalized the drug in legislation popularly known as “medical marijuana” or “recreational marijuana”. Cannabis compounds and derivatives hold strong promise to add to the pharmacopeia of medicines employed in human healthcare that would expand alternatives of medical treatment modes.
Keywords: CBD, Delta9-THC, Type II Diabetes, anti-inflammatory activity, psychogenic effects
Cite this ArticleFlaer P. Activity of Cannabinoids in Type II Diabetes. Research and Reviews: Journal of Neuroscience. 2017; 7(2): 1–5p.